| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 259 | 2025 | 2150 | 30.310 |
Why?
|
| Heart-Assist Devices | 64 | 2024 | 539 | 12.990 |
Why?
|
| Stroke Volume | 51 | 2025 | 592 | 5.920 |
Why?
|
| Atrial Fibrillation | 39 | 2024 | 376 | 5.620 |
Why?
|
| Decision Making | 26 | 2024 | 851 | 4.500 |
Why?
|
| Patient Readmission | 28 | 2024 | 667 | 4.290 |
Why?
|
| Decision Support Techniques | 16 | 2022 | 396 | 3.630 |
Why?
|
| Registries | 50 | 2024 | 1896 | 3.590 |
Why?
|
| Quality of Life | 47 | 2024 | 2704 | 3.340 |
Why?
|
| Ventricular Dysfunction, Left | 15 | 2023 | 385 | 3.260 |
Why?
|
| Palliative Care | 23 | 2025 | 725 | 3.100 |
Why?
|
| Health Expenditures | 8 | 2025 | 179 | 2.970 |
Why?
|
| Cardiology | 20 | 2025 | 261 | 2.940 |
Why?
|
| Heart Transplantation | 17 | 2024 | 721 | 2.830 |
Why?
|
| Drug Costs | 6 | 2025 | 100 | 2.720 |
Why?
|
| Humans | 351 | 2025 | 129650 | 2.680 |
Why?
|
| Ventricular Function, Left | 18 | 2024 | 527 | 2.640 |
Why?
|
| Guideline Adherence | 14 | 2025 | 526 | 2.530 |
Why?
|
| Patient Participation | 16 | 2025 | 414 | 2.510 |
Why?
|
| Aged | 147 | 2025 | 22103 | 2.360 |
Why?
|
| Caregivers | 18 | 2025 | 815 | 2.350 |
Why?
|
| Hospitalization | 47 | 2025 | 2070 | 2.260 |
Why?
|
| United States | 117 | 2025 | 13903 | 2.200 |
Why?
|
| Hospice Care | 9 | 2021 | 200 | 2.170 |
Why?
|
| Cardiovascular Agents | 6 | 2025 | 156 | 2.170 |
Why?
|
| Defibrillators, Implantable | 15 | 2022 | 300 | 2.130 |
Why?
|
| Patient Discharge | 28 | 2024 | 857 | 2.000 |
Why?
|
| Anticoagulants | 18 | 2024 | 637 | 1.960 |
Why?
|
| Ambulatory Care | 9 | 2025 | 504 | 1.870 |
Why?
|
| Practice Patterns, Physicians' | 12 | 2024 | 1266 | 1.850 |
Why?
|
| Medicare | 31 | 2024 | 720 | 1.810 |
Why?
|
| Terminal Care | 9 | 2020 | 237 | 1.800 |
Why?
|
| Middle Aged | 118 | 2025 | 31154 | 1.780 |
Why?
|
| Male | 171 | 2025 | 63681 | 1.770 |
Why?
|
| Risk Assessment | 34 | 2025 | 3240 | 1.740 |
Why?
|
| Female | 176 | 2025 | 68776 | 1.710 |
Why?
|
| Aged, 80 and over | 66 | 2025 | 7086 | 1.710 |
Why?
|
| Practice Guidelines as Topic | 16 | 2025 | 1501 | 1.660 |
Why?
|
| Cardiotonic Agents | 10 | 2021 | 126 | 1.650 |
Why?
|
| Stroke | 16 | 2024 | 1071 | 1.630 |
Why?
|
| American Heart Association | 19 | 2025 | 296 | 1.610 |
Why?
|
| Outpatients | 10 | 2023 | 370 | 1.590 |
Why?
|
| Patient Preference | 6 | 2018 | 185 | 1.550 |
Why?
|
| Treatment Outcome | 58 | 2025 | 10230 | 1.490 |
Why?
|
| Angiotensin Receptor Antagonists | 13 | 2025 | 89 | 1.450 |
Why?
|
| Health Status | 14 | 2023 | 755 | 1.420 |
Why?
|
| Myocardial Infarction | 9 | 2023 | 1022 | 1.390 |
Why?
|
| Patient-Centered Care | 12 | 2024 | 505 | 1.330 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2025 | 1368 | 1.310 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 10 | 2024 | 198 | 1.310 |
Why?
|
| Hemorrhage | 11 | 2024 | 678 | 1.280 |
Why?
|
| Withholding Treatment | 5 | 2019 | 71 | 1.280 |
Why?
|
| Delivery of Health Care | 11 | 2023 | 894 | 1.240 |
Why?
|
| Adrenergic beta-Antagonists | 10 | 2025 | 321 | 1.240 |
Why?
|
| Prognosis | 30 | 2024 | 3794 | 1.240 |
Why?
|
| Heart Ventricles | 6 | 2021 | 781 | 1.240 |
Why?
|
| Aminobutyrates | 7 | 2023 | 33 | 1.220 |
Why?
|
| Inpatients | 5 | 2023 | 467 | 1.210 |
Why?
|
| Aftercare | 17 | 2023 | 205 | 1.190 |
Why?
|
| Family | 4 | 2023 | 657 | 1.170 |
Why?
|
| Hospitals | 10 | 2024 | 637 | 1.150 |
Why?
|
| Risk Factors | 49 | 2025 | 9765 | 1.150 |
Why?
|
| Health Care Costs | 8 | 2024 | 367 | 1.080 |
Why?
|
| Cardiovascular Diseases | 15 | 2025 | 2004 | 1.070 |
Why?
|
| Valsartan | 6 | 2022 | 27 | 1.060 |
Why?
|
| Patient Care Management | 3 | 2017 | 56 | 1.050 |
Why?
|
| Biphenyl Compounds | 7 | 2022 | 60 | 1.050 |
Why?
|
| Cardiovascular System | 6 | 2024 | 137 | 1.040 |
Why?
|
| Cost of Illness | 6 | 2024 | 278 | 1.030 |
Why?
|
| Clinical Decision-Making | 9 | 2024 | 303 | 1.010 |
Why?
|
| Surveys and Questionnaires | 23 | 2024 | 5406 | 1.010 |
Why?
|
| Consumer Health Information | 3 | 2017 | 49 | 1.010 |
Why?
|
| Quality Improvement | 8 | 2025 | 1103 | 1.000 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2021 | 1279 | 0.990 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 7 | 2025 | 46 | 0.960 |
Why?
|
| Death, Sudden, Cardiac | 5 | 2025 | 179 | 0.950 |
Why?
|
| Heart Failure, Systolic | 3 | 2018 | 25 | 0.940 |
Why?
|
| Patient Selection | 10 | 2019 | 663 | 0.930 |
Why?
|
| Patient Reported Outcome Measures | 11 | 2024 | 373 | 0.930 |
Why?
|
| Acute Coronary Syndrome | 2 | 2023 | 267 | 0.920 |
Why?
|
| Internet | 4 | 2020 | 617 | 0.910 |
Why?
|
| Biomedical Research | 3 | 2020 | 638 | 0.900 |
Why?
|
| Anti-Arrhythmia Agents | 4 | 2020 | 111 | 0.890 |
Why?
|
| Symporters | 1 | 2024 | 56 | 0.880 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2020 | 36 | 0.870 |
Why?
|
| Survival Analysis | 14 | 2019 | 1274 | 0.850 |
Why?
|
| Patient Education as Topic | 4 | 2018 | 743 | 0.850 |
Why?
|
| Follow-Up Studies | 26 | 2024 | 4897 | 0.840 |
Why?
|
| Quality of Health Care | 8 | 2024 | 608 | 0.840 |
Why?
|
| Cannabis | 3 | 2024 | 465 | 0.840 |
Why?
|
| Medication Adherence | 7 | 2025 | 558 | 0.840 |
Why?
|
| Protease Inhibitors | 2 | 2020 | 106 | 0.830 |
Why?
|
| Heart Injuries | 1 | 2023 | 36 | 0.810 |
Why?
|
| Physicians | 7 | 2023 | 865 | 0.790 |
Why?
|
| Spirituality | 1 | 2023 | 80 | 0.770 |
Why?
|
| Diuretics | 4 | 2023 | 76 | 0.750 |
Why?
|
| Informed Consent | 3 | 2023 | 170 | 0.730 |
Why?
|
| Device Removal | 2 | 2020 | 136 | 0.730 |
Why?
|
| Patient Care Team | 5 | 2024 | 605 | 0.720 |
Why?
|
| Catheter Ablation | 4 | 2020 | 335 | 0.710 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2023 | 467 | 0.710 |
Why?
|
| Quality Indicators, Health Care | 8 | 2025 | 298 | 0.710 |
Why?
|
| Insurance, Health | 3 | 2017 | 267 | 0.700 |
Why?
|
| Transitional Care | 3 | 2021 | 37 | 0.700 |
Why?
|
| Biomarkers | 8 | 2024 | 3973 | 0.690 |
Why?
|
| Health Policy | 3 | 2021 | 353 | 0.680 |
Why?
|
| Societies, Medical | 6 | 2024 | 751 | 0.670 |
Why?
|
| Retrospective Studies | 39 | 2024 | 14518 | 0.660 |
Why?
|
| Length of Stay | 7 | 2018 | 1127 | 0.650 |
Why?
|
| Adult | 51 | 2024 | 35576 | 0.650 |
Why?
|
| Attitude to Death | 4 | 2023 | 67 | 0.650 |
Why?
|
| Population Health | 1 | 2020 | 46 | 0.650 |
Why?
|
| Cause of Death | 8 | 2020 | 393 | 0.640 |
Why?
|
| Patient Rights | 1 | 2019 | 11 | 0.640 |
Why?
|
| Drug Substitution | 2 | 2018 | 51 | 0.630 |
Why?
|
| Time Factors | 23 | 2024 | 6556 | 0.630 |
Why?
|
| Cardiomyopathies | 3 | 2015 | 340 | 0.620 |
Why?
|
| Propanolamines | 1 | 2019 | 97 | 0.620 |
Why?
|
| Telemedicine | 6 | 2024 | 788 | 0.610 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 341 | 0.610 |
Why?
|
| Medicaid | 4 | 2021 | 433 | 0.610 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 335 | 0.600 |
Why?
|
| Quality Assurance, Health Care | 3 | 2015 | 318 | 0.600 |
Why?
|
| Hospices | 5 | 2021 | 89 | 0.580 |
Why?
|
| Health Status Indicators | 3 | 2020 | 167 | 0.580 |
Why?
|
| Manuscripts, Medical as Topic | 1 | 2017 | 5 | 0.580 |
Why?
|
| Warfarin | 7 | 2022 | 147 | 0.570 |
Why?
|
| Interviews as Topic | 9 | 2021 | 717 | 0.570 |
Why?
|
| Heart Diseases | 2 | 2014 | 350 | 0.570 |
Why?
|
| Attitude to Health | 4 | 2019 | 431 | 0.560 |
Why?
|
| Cocaine | 1 | 2019 | 149 | 0.560 |
Why?
|
| Peer Review | 1 | 2017 | 49 | 0.560 |
Why?
|
| Peer Review, Research | 1 | 2017 | 41 | 0.560 |
Why?
|
| Disease Progression | 15 | 2025 | 2635 | 0.550 |
Why?
|
| Editorial Policies | 1 | 2017 | 48 | 0.540 |
Why?
|
| Physician-Patient Relations | 3 | 2020 | 539 | 0.540 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2021 | 177 | 0.540 |
Why?
|
| Insurance Claim Review | 2 | 2014 | 64 | 0.530 |
Why?
|
| Consensus | 8 | 2024 | 616 | 0.530 |
Why?
|
| Stress, Psychological | 3 | 2021 | 1066 | 0.530 |
Why?
|
| Advance Care Planning | 2 | 2019 | 205 | 0.530 |
Why?
|
| Angina, Unstable | 3 | 2006 | 76 | 0.520 |
Why?
|
| Aortic Valve Stenosis | 2 | 2021 | 218 | 0.520 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 137 | 0.520 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 2441 | 0.520 |
Why?
|
| Prospective Studies | 20 | 2022 | 7133 | 0.500 |
Why?
|
| Disease Management | 6 | 2022 | 589 | 0.500 |
Why?
|
| Comorbidity | 13 | 2023 | 1547 | 0.500 |
Why?
|
| Digoxin | 1 | 2015 | 27 | 0.490 |
Why?
|
| Clinical Trials as Topic | 6 | 2019 | 1004 | 0.490 |
Why?
|
| Appointments and Schedules | 1 | 2016 | 84 | 0.480 |
Why?
|
| Survival Rate | 10 | 2020 | 1877 | 0.480 |
Why?
|
| Acute Disease | 8 | 2024 | 980 | 0.480 |
Why?
|
| Natriuretic Peptide, Brain | 5 | 2022 | 99 | 0.470 |
Why?
|
| Periodicals as Topic | 1 | 2017 | 204 | 0.470 |
Why?
|
| Multimedia | 1 | 2014 | 9 | 0.470 |
Why?
|
| Heart Rate | 4 | 2020 | 802 | 0.460 |
Why?
|
| Frail Elderly | 2 | 2013 | 121 | 0.460 |
Why?
|
| Healthcare Disparities | 7 | 2023 | 578 | 0.460 |
Why?
|
| Cohort Studies | 16 | 2023 | 5420 | 0.450 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 384 | 0.450 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 248 | 0.450 |
Why?
|
| Neprilysin | 4 | 2024 | 48 | 0.450 |
Why?
|
| Proportional Hazards Models | 13 | 2019 | 1201 | 0.450 |
Why?
|
| Skilled Nursing Facilities | 2 | 2016 | 131 | 0.440 |
Why?
|
| Cost-Benefit Analysis | 5 | 2024 | 569 | 0.440 |
Why?
|
| Qualitative Research | 11 | 2025 | 1235 | 0.440 |
Why?
|
| Health Personnel | 2 | 2022 | 652 | 0.430 |
Why?
|
| Fluid Therapy | 1 | 2015 | 134 | 0.430 |
Why?
|
| Population Surveillance | 1 | 2017 | 439 | 0.430 |
Why?
|
| Hip Prosthesis | 1 | 2014 | 37 | 0.430 |
Why?
|
| Colorado | 12 | 2021 | 4421 | 0.430 |
Why?
|
| Severity of Illness Index | 8 | 2018 | 2742 | 0.430 |
Why?
|
| Hyperkalemia | 1 | 2013 | 24 | 0.430 |
Why?
|
| Shock, Cardiogenic | 1 | 2014 | 60 | 0.430 |
Why?
|
| Socioeconomic Factors | 6 | 2022 | 1214 | 0.420 |
Why?
|
| Chest Pain | 2 | 2024 | 89 | 0.420 |
Why?
|
| Hospital Mortality | 8 | 2023 | 850 | 0.420 |
Why?
|
| Marijuana Abuse | 1 | 2016 | 234 | 0.420 |
Why?
|
| Preoperative Period | 1 | 2013 | 115 | 0.420 |
Why?
|
| Tetrazoles | 6 | 2023 | 38 | 0.420 |
Why?
|
| Hand Strength | 1 | 2014 | 113 | 0.420 |
Why?
|
| Prosthesis Failure | 1 | 2014 | 114 | 0.410 |
Why?
|
| Life Expectancy | 2 | 2016 | 61 | 0.410 |
Why?
|
| Electrocardiography | 5 | 2023 | 608 | 0.410 |
Why?
|
| Models, Statistical | 2 | 2014 | 623 | 0.400 |
Why?
|
| Patient Admission | 3 | 2015 | 182 | 0.400 |
Why?
|
| Drug Combinations | 7 | 2022 | 330 | 0.400 |
Why?
|
| Cardiac Catheterization | 3 | 2020 | 518 | 0.390 |
Why?
|
| Aortic Valve | 2 | 2021 | 348 | 0.390 |
Why?
|
| Algorithms | 4 | 2022 | 1622 | 0.390 |
Why?
|
| Furosemide | 2 | 2023 | 39 | 0.390 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2022 | 317 | 0.390 |
Why?
|
| Coronary Artery Bypass | 2 | 2011 | 224 | 0.380 |
Why?
|
| Sex Factors | 9 | 2024 | 1968 | 0.380 |
Why?
|
| Chronic Disease | 10 | 2022 | 1720 | 0.380 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 149 | 0.370 |
Why?
|
| Cross-Sectional Studies | 10 | 2024 | 5066 | 0.370 |
Why?
|
| Social Environment | 1 | 2013 | 292 | 0.360 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 481 | 0.360 |
Why?
|
| Eligibility Determination | 3 | 2024 | 63 | 0.360 |
Why?
|
| Health Literacy | 4 | 2022 | 161 | 0.360 |
Why?
|
| Myocarditis | 2 | 2022 | 98 | 0.350 |
Why?
|
| Text Messaging | 2 | 2025 | 149 | 0.350 |
Why?
|
| Emotions | 7 | 2023 | 538 | 0.350 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2024 | 442 | 0.350 |
Why?
|
| Income | 3 | 2020 | 189 | 0.350 |
Why?
|
| Adaptation, Psychological | 7 | 2023 | 617 | 0.350 |
Why?
|
| Age Factors | 12 | 2020 | 3144 | 0.340 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2023 | 205 | 0.340 |
Why?
|
| Research Report | 5 | 2022 | 76 | 0.340 |
Why?
|
| Patient Protection and Affordable Care Act | 3 | 2017 | 100 | 0.340 |
Why?
|
| Risk | 4 | 2019 | 854 | 0.340 |
Why?
|
| Erythrocyte Indices | 1 | 2009 | 27 | 0.330 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2020 | 275 | 0.330 |
Why?
|
| Communication | 5 | 2023 | 846 | 0.320 |
Why?
|
| Cardiologists | 3 | 2018 | 45 | 0.320 |
Why?
|
| Poverty | 1 | 2013 | 496 | 0.320 |
Why?
|
| Drug Therapy, Combination | 3 | 2024 | 1040 | 0.310 |
Why?
|
| Weights and Measures | 1 | 2008 | 7 | 0.310 |
Why?
|
| Liver Function Tests | 1 | 2009 | 112 | 0.300 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2021 | 248 | 0.300 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2021 | 566 | 0.300 |
Why?
|
| Hemodynamics | 5 | 2023 | 1090 | 0.300 |
Why?
|
| Anemia | 1 | 2009 | 160 | 0.300 |
Why?
|
| Administration, Oral | 9 | 2021 | 786 | 0.290 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 170 | 0.290 |
Why?
|
| Pain | 2 | 2018 | 789 | 0.290 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 283 | 0.290 |
Why?
|
| Patient Satisfaction | 5 | 2024 | 634 | 0.290 |
Why?
|
| Research Design | 5 | 2023 | 1044 | 0.290 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2008 | 67 | 0.280 |
Why?
|
| Internationality | 1 | 2008 | 149 | 0.280 |
Why?
|
| Mitral Valve | 1 | 2008 | 85 | 0.280 |
Why?
|
| Multivariate Analysis | 7 | 2013 | 1502 | 0.280 |
Why?
|
| Betacoronavirus | 2 | 2020 | 249 | 0.280 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2022 | 45 | 0.280 |
Why?
|
| Erythrocytes | 2 | 2009 | 672 | 0.270 |
Why?
|
| Incidence | 10 | 2018 | 2644 | 0.270 |
Why?
|
| Models, Cardiovascular | 1 | 2008 | 191 | 0.270 |
Why?
|
| Hospitals, Community | 2 | 2020 | 48 | 0.270 |
Why?
|
| Congresses as Topic | 4 | 2025 | 216 | 0.270 |
Why?
|
| Cognitive Dysfunction | 2 | 2024 | 346 | 0.260 |
Why?
|
| Troponin | 2 | 2024 | 50 | 0.260 |
Why?
|
| Choice Behavior | 2 | 2020 | 165 | 0.260 |
Why?
|
| Referral and Consultation | 5 | 2023 | 732 | 0.260 |
Why?
|
| Prosthesis Design | 4 | 2018 | 306 | 0.260 |
Why?
|
| Patient Care | 2 | 2023 | 109 | 0.260 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 2142 | 0.250 |
Why?
|
| Sodium | 2 | 2024 | 206 | 0.250 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 790 | 0.250 |
Why?
|
| Evidence-Based Medicine | 4 | 2021 | 718 | 0.250 |
Why?
|
| Prosthesis Implantation | 2 | 2019 | 145 | 0.240 |
Why?
|
| Pilot Projects | 6 | 2022 | 1587 | 0.240 |
Why?
|
| Frailty | 2 | 2019 | 153 | 0.240 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2025 | 14 | 0.240 |
Why?
|
| Patient Compliance | 4 | 2019 | 565 | 0.240 |
Why?
|
| Marijuana Smoking | 2 | 2020 | 247 | 0.240 |
Why?
|
| Electric Countershock | 3 | 2020 | 105 | 0.230 |
Why?
|
| Prevalence | 9 | 2020 | 2564 | 0.230 |
Why?
|
| Mass Screening | 2 | 2010 | 1149 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 857 | 0.230 |
Why?
|
| Mortality | 4 | 2020 | 307 | 0.230 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2020 | 759 | 0.230 |
Why?
|
| Digital Divide | 1 | 2024 | 3 | 0.220 |
Why?
|
| Checklist | 1 | 2024 | 94 | 0.220 |
Why?
|
| Mobile Applications | 2 | 2024 | 160 | 0.220 |
Why?
|
| Infusions, Intravenous | 3 | 2018 | 400 | 0.210 |
Why?
|
| Creatinine | 3 | 2023 | 491 | 0.210 |
Why?
|
| Clinical Coding | 2 | 2014 | 20 | 0.210 |
Why?
|
| Neoplasms | 3 | 2023 | 2470 | 0.210 |
Why?
|
| Cognition | 5 | 2024 | 1123 | 0.210 |
Why?
|
| Probability | 3 | 2016 | 306 | 0.210 |
Why?
|
| Primary Prevention | 1 | 2025 | 188 | 0.210 |
Why?
|
| Sports Medicine | 1 | 2025 | 110 | 0.210 |
Why?
|
| Depression | 4 | 2020 | 1307 | 0.210 |
Why?
|
| Urea | 1 | 2023 | 77 | 0.210 |
Why?
|
| Isosorbide Dinitrate | 1 | 2023 | 3 | 0.210 |
Why?
|
| Hydralazine | 1 | 2023 | 4 | 0.210 |
Why?
|
| Self Care | 4 | 2024 | 370 | 0.210 |
Why?
|
| Denmark | 1 | 2023 | 44 | 0.210 |
Why?
|
| Reproducibility of Results | 5 | 2023 | 3083 | 0.210 |
Why?
|
| Cardiac Rehabilitation | 1 | 2023 | 34 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 2 | 2024 | 286 | 0.210 |
Why?
|
| Drug Utilization | 2 | 2015 | 171 | 0.210 |
Why?
|
| Reminder Systems | 1 | 2025 | 174 | 0.200 |
Why?
|
| Perinatal Care | 1 | 2023 | 54 | 0.200 |
Why?
|
| Medical Marijuana | 2 | 2024 | 111 | 0.200 |
Why?
|
| Death | 1 | 2023 | 121 | 0.200 |
Why?
|
| Atrial Appendage | 1 | 2022 | 15 | 0.200 |
Why?
|
| Recovery of Function | 4 | 2020 | 642 | 0.200 |
Why?
|
| Pulmonary Artery | 1 | 2008 | 1096 | 0.190 |
Why?
|
| Sports | 1 | 2025 | 225 | 0.190 |
Why?
|
| Patient Care Bundles | 1 | 2021 | 20 | 0.190 |
Why?
|
| Pandemics | 2 | 2020 | 1488 | 0.190 |
Why?
|
| Glucose | 2 | 2024 | 1003 | 0.190 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2021 | 79 | 0.180 |
Why?
|
| Advisory Committees | 2 | 2021 | 216 | 0.180 |
Why?
|
| Social Determinants of Health | 2 | 2024 | 221 | 0.180 |
Why?
|
| Trust | 1 | 2022 | 116 | 0.180 |
Why?
|
| Athletes | 1 | 2025 | 409 | 0.180 |
Why?
|
| Universities | 1 | 2023 | 408 | 0.180 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2021 | 94 | 0.180 |
Why?
|
| Age Distribution | 3 | 2012 | 372 | 0.180 |
Why?
|
| Myocardial Contraction | 2 | 2019 | 335 | 0.180 |
Why?
|
| Anxiety | 3 | 2018 | 966 | 0.180 |
Why?
|
| Relaxin | 1 | 2020 | 18 | 0.180 |
Why?
|
| Norway | 1 | 2020 | 42 | 0.180 |
Why?
|
| Georgia | 1 | 2020 | 79 | 0.180 |
Why?
|
| Health Systems Plans | 1 | 2020 | 3 | 0.170 |
Why?
|
| Financing, Government | 1 | 2020 | 43 | 0.170 |
Why?
|
| Psychology | 1 | 2021 | 82 | 0.170 |
Why?
|
| Health Services Misuse | 1 | 2020 | 35 | 0.170 |
Why?
|
| Hypertension | 3 | 2021 | 1242 | 0.170 |
Why?
|
| Palliative Medicine | 2 | 2018 | 15 | 0.170 |
Why?
|
| Health Resources | 2 | 2012 | 114 | 0.170 |
Why?
|
| Home Care Services | 2 | 2020 | 246 | 0.170 |
Why?
|
| Self Report | 1 | 2024 | 799 | 0.170 |
Why?
|
| Diagnosis-Related Groups | 2 | 2021 | 28 | 0.170 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 123 | 0.170 |
Why?
|
| Thoracentesis | 1 | 2019 | 5 | 0.170 |
Why?
|
| Odds Ratio | 5 | 2014 | 1023 | 0.160 |
Why?
|
| Pyridones | 1 | 2021 | 159 | 0.160 |
Why?
|
| Mandatory Programs | 1 | 2019 | 15 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 171 | 0.160 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 151 | 0.160 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2019 | 13 | 0.160 |
Why?
|
| Nurses | 3 | 2018 | 164 | 0.160 |
Why?
|
| Mental Competency | 1 | 2019 | 27 | 0.160 |
Why?
|
| Dyspnea | 3 | 2018 | 242 | 0.160 |
Why?
|
| Fatigue | 3 | 2018 | 318 | 0.150 |
Why?
|
| Home Infusion Therapy | 1 | 2018 | 4 | 0.150 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 282 | 0.150 |
Why?
|
| Fee-for-Service Plans | 2 | 2018 | 88 | 0.150 |
Why?
|
| Guidelines as Topic | 2 | 2017 | 264 | 0.150 |
Why?
|
| Contraindications | 2 | 2015 | 90 | 0.150 |
Why?
|
| Cooperative Behavior | 2 | 2024 | 433 | 0.150 |
Why?
|
| Coronary Artery Disease | 3 | 2019 | 679 | 0.150 |
Why?
|
| Atherosclerosis | 1 | 2022 | 402 | 0.150 |
Why?
|
| Ventricular Function | 1 | 2018 | 61 | 0.150 |
Why?
|
| Heart Failure, Diastolic | 1 | 2018 | 21 | 0.150 |
Why?
|
| Patient Safety | 3 | 2021 | 287 | 0.150 |
Why?
|
| Thromboembolism | 2 | 2021 | 112 | 0.150 |
Why?
|
| Reimbursement Mechanisms | 1 | 2018 | 84 | 0.140 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 769 | 0.140 |
Why?
|
| Cost Savings | 2 | 2021 | 78 | 0.140 |
Why?
|
| Heart Conduction System | 1 | 2018 | 95 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 2012 | 0.140 |
Why?
|
| Attitude of Health Personnel | 3 | 2020 | 1098 | 0.140 |
Why?
|
| Spouses | 1 | 2018 | 100 | 0.140 |
Why?
|
| Medical Records | 1 | 2018 | 171 | 0.140 |
Why?
|
| Quality Control | 1 | 2017 | 163 | 0.140 |
Why?
|
| Thrombosis | 1 | 2021 | 343 | 0.140 |
Why?
|
| Spiritual Therapies | 1 | 2017 | 12 | 0.140 |
Why?
|
| Vaccines | 1 | 2022 | 398 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 252 | 0.130 |
Why?
|
| Caliciviridae Infections | 1 | 2016 | 17 | 0.130 |
Why?
|
| Blood Coagulation | 1 | 2018 | 238 | 0.130 |
Why?
|
| Mental Health | 1 | 2023 | 686 | 0.130 |
Why?
|
| Mexiletine | 1 | 2016 | 6 | 0.130 |
Why?
|
| Amphetamine | 1 | 2016 | 25 | 0.130 |
Why?
|
| Defibrillators | 1 | 2016 | 16 | 0.130 |
Why?
|
| Pain Management | 2 | 2016 | 327 | 0.130 |
Why?
|
| Thrombolytic Therapy | 1 | 2017 | 137 | 0.130 |
Why?
|
| Truth Disclosure | 1 | 2016 | 44 | 0.130 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1952 | 0.130 |
Why?
|
| Bereavement | 1 | 2016 | 50 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2012 | 1269 | 0.120 |
Why?
|
| Public Health | 1 | 2020 | 484 | 0.120 |
Why?
|
| Psychotherapy | 1 | 2017 | 157 | 0.120 |
Why?
|
| Uncertainty | 1 | 2016 | 116 | 0.120 |
Why?
|
| Social Security | 1 | 2015 | 5 | 0.120 |
Why?
|
| Medical Indigency | 1 | 2015 | 11 | 0.120 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 1902 | 0.120 |
Why?
|
| Substance Abuse Detection | 1 | 2016 | 79 | 0.120 |
Why?
|
| Antihypertensive Agents | 2 | 2023 | 485 | 0.120 |
Why?
|
| Transplant Recipients | 1 | 2016 | 162 | 0.120 |
Why?
|
| Information Seeking Behavior | 1 | 2015 | 33 | 0.120 |
Why?
|
| Waiting Lists | 1 | 2017 | 237 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2016 | 216 | 0.110 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2014 | 25 | 0.110 |
Why?
|
| Polypharmacy | 1 | 2015 | 84 | 0.110 |
Why?
|
| Assisted Circulation | 1 | 2014 | 26 | 0.110 |
Why?
|
| Drug Hypersensitivity | 1 | 2015 | 81 | 0.110 |
Why?
|
| Kidney | 2 | 2020 | 1385 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 125 | 0.110 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2015 | 78 | 0.110 |
Why?
|
| Health Surveys | 3 | 2023 | 494 | 0.110 |
Why?
|
| Cobalt | 1 | 2014 | 50 | 0.110 |
Why?
|
| Young Adult | 7 | 2019 | 12426 | 0.110 |
Why?
|
| Potassium | 1 | 2013 | 143 | 0.100 |
Why?
|
| Critical Care | 1 | 2018 | 553 | 0.100 |
Why?
|
| Data Collection | 1 | 2016 | 650 | 0.100 |
Why?
|
| Calcium | 1 | 2019 | 1213 | 0.100 |
Why?
|
| Anthracyclines | 1 | 2012 | 49 | 0.100 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 457 | 0.100 |
Why?
|
| Women's Health | 1 | 2015 | 365 | 0.100 |
Why?
|
| Health Maintenance Organizations | 1 | 2012 | 97 | 0.100 |
Why?
|
| Drug Utilization Review | 1 | 2012 | 57 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 2061 | 0.100 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 205 | 0.100 |
Why?
|
| Infant, Newborn | 1 | 2023 | 5762 | 0.100 |
Why?
|
| Patients | 2 | 2024 | 167 | 0.090 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 55 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 268 | 0.090 |
Why?
|
| Acculturation | 1 | 2012 | 50 | 0.090 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2012 | 48 | 0.090 |
Why?
|
| Tachycardia | 1 | 2011 | 57 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 1001 | 0.090 |
Why?
|
| Hyponatremia | 1 | 2011 | 40 | 0.090 |
Why?
|
| Culture | 1 | 2012 | 124 | 0.090 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 258 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2019 | 2273 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2015 | 505 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2017 | 742 | 0.090 |
Why?
|
| Echocardiography | 1 | 2014 | 629 | 0.090 |
Why?
|
| Pregnancy | 1 | 2023 | 6402 | 0.090 |
Why?
|
| Motivation | 1 | 2015 | 546 | 0.090 |
Why?
|
| Logistic Models | 2 | 2013 | 1988 | 0.090 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2010 | 8 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 985 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 2 | 2013 | 711 | 0.080 |
Why?
|
| Health Services Research | 1 | 2013 | 391 | 0.080 |
Why?
|
| Confidence Intervals | 3 | 2020 | 317 | 0.080 |
Why?
|
| Benzazepines | 1 | 2010 | 40 | 0.080 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 201 | 0.080 |
Why?
|
| Erythropoiesis | 1 | 2009 | 51 | 0.080 |
Why?
|
| Minority Groups | 1 | 2012 | 249 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1434 | 0.080 |
Why?
|
| Electric Stimulation Therapy | 1 | 2010 | 77 | 0.080 |
Why?
|
| Focus Groups | 2 | 2023 | 453 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 430 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2009 | 76 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2009 | 88 | 0.080 |
Why?
|
| Bilirubin | 1 | 2009 | 96 | 0.080 |
Why?
|
| ROC Curve | 1 | 2010 | 503 | 0.080 |
Why?
|
| Alberta | 1 | 2008 | 14 | 0.080 |
Why?
|
| Actuarial Analysis | 1 | 2008 | 26 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 335 | 0.080 |
Why?
|
| Syndrome | 1 | 2009 | 341 | 0.070 |
Why?
|
| Alkaline Phosphatase | 1 | 2009 | 146 | 0.070 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 153 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 204 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2009 | 149 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2011 | 328 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 2344 | 0.070 |
Why?
|
| DNA | 1 | 2014 | 1400 | 0.070 |
Why?
|
| Insurance Coverage | 2 | 2021 | 219 | 0.070 |
Why?
|
| Substance-Related Disorders | 1 | 2016 | 1022 | 0.070 |
Why?
|
| Social Support | 3 | 2019 | 588 | 0.070 |
Why?
|
| Ultrafiltration | 1 | 2007 | 28 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 759 | 0.070 |
Why?
|
| Social Workers | 2 | 2018 | 39 | 0.070 |
Why?
|
| Heart Function Tests | 1 | 2007 | 59 | 0.070 |
Why?
|
| Child | 2 | 2023 | 20883 | 0.070 |
Why?
|
| Precision Medicine | 2 | 2024 | 387 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2007 | 162 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2009 | 290 | 0.060 |
Why?
|
| Lung | 1 | 2018 | 3930 | 0.060 |
Why?
|
| Genomics | 1 | 2010 | 716 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2007 | 326 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2020 | 868 | 0.060 |
Why?
|
| Review Literature as Topic | 1 | 2025 | 66 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2006 | 224 | 0.060 |
Why?
|
| Troponin T | 1 | 2024 | 57 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 902 | 0.060 |
Why?
|
| Natriuretic Peptides | 1 | 2023 | 9 | 0.060 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2024 | 62 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 1206 | 0.050 |
Why?
|
| Troponin I | 1 | 2024 | 75 | 0.050 |
Why?
|
| Group Processes | 1 | 2024 | 57 | 0.050 |
Why?
|
| Proteomics | 1 | 2010 | 1062 | 0.050 |
Why?
|
| Prescriptions | 1 | 2023 | 66 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2023 | 156 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2023 | 82 | 0.050 |
Why?
|
| Heuristics | 1 | 2022 | 8 | 0.050 |
Why?
|
| Information Systems | 1 | 2023 | 61 | 0.050 |
Why?
|
| Critical Illness | 1 | 2008 | 758 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2008 | 499 | 0.050 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 15 | 0.050 |
Why?
|
| Sexism | 1 | 2023 | 55 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2022 | 46 | 0.050 |
Why?
|
| Massachusetts | 1 | 2022 | 159 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3408 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2024 | 277 | 0.050 |
Why?
|
| Program Development | 1 | 2023 | 357 | 0.050 |
Why?
|
| Return to Sport | 1 | 2022 | 90 | 0.050 |
Why?
|
| Phenotype | 2 | 2021 | 3076 | 0.050 |
Why?
|
| Critical Pathways | 1 | 2022 | 80 | 0.040 |
Why?
|
| Policy | 1 | 2022 | 144 | 0.040 |
Why?
|
| Urban Health Services | 1 | 2020 | 61 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 339 | 0.040 |
Why?
|
| Attitude | 1 | 2022 | 253 | 0.040 |
Why?
|
| Exercise Test | 1 | 2023 | 613 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 246 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 122 | 0.040 |
Why?
|
| Organizations, Nonprofit | 1 | 2020 | 17 | 0.040 |
Why?
|
| Private Sector | 1 | 2020 | 50 | 0.040 |
Why?
|
| Intracranial Embolism | 1 | 2019 | 31 | 0.040 |
Why?
|
| Public Opinion | 1 | 2020 | 64 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 77 | 0.040 |
Why?
|
| Rural Health Services | 1 | 2020 | 111 | 0.040 |
Why?
|
| Embolism | 1 | 2019 | 40 | 0.040 |
Why?
|
| Contraindications, Procedure | 1 | 2019 | 11 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 350 | 0.040 |
Why?
|
| Visual Analog Scale | 1 | 2019 | 29 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 333 | 0.040 |
Why?
|
| Myocardial Revascularization | 1 | 2019 | 72 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 126 | 0.040 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2019 | 102 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 110 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 126 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 106 | 0.040 |
Why?
|
| Government Regulation | 1 | 2018 | 49 | 0.040 |
Why?
|
| Survival | 1 | 2018 | 39 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 340 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2023 | 737 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 22 | 0.040 |
Why?
|
| Hospitals, Rural | 1 | 2018 | 37 | 0.040 |
Why?
|
| Policy Making | 1 | 2018 | 88 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1838 | 0.040 |
Why?
|
| Walk Test | 1 | 2018 | 70 | 0.040 |
Why?
|
| Medicare Part D | 1 | 2018 | 24 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2022 | 692 | 0.040 |
Why?
|
| Patient Health Questionnaire | 1 | 2018 | 36 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2018 | 129 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 346 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 209 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2018 | 271 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1304 | 0.030 |
Why?
|
| Risk Management | 1 | 2018 | 85 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 273 | 0.030 |
Why?
|
| Diphenoxylate | 1 | 2016 | 5 | 0.030 |
Why?
|
| Atropine | 1 | 2016 | 24 | 0.030 |
Why?
|
| Loperamide | 1 | 2016 | 11 | 0.030 |
Why?
|
| Antidiarrheals | 1 | 2016 | 15 | 0.030 |
Why?
|
| Emotional Adjustment | 1 | 2016 | 16 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 2717 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2016 | 38 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 265 | 0.030 |
Why?
|
| Voltage-Gated Sodium Channel Blockers | 1 | 2016 | 5 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2016 | 32 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2018 | 482 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 61 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 752 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2017 | 127 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 329 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 1016 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2016 | 125 | 0.030 |
Why?
|
| Data Accuracy | 1 | 2016 | 57 | 0.030 |
Why?
|
| Video Recording | 1 | 2016 | 164 | 0.030 |
Why?
|
| Physicians, Primary Care | 1 | 2018 | 230 | 0.030 |
Why?
|
| Life Change Events | 1 | 2016 | 148 | 0.030 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2014 | 28 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 154 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 793 | 0.030 |
Why?
|
| Family Relations | 1 | 2015 | 88 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 2015 | 89 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 819 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 1038 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 302 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 387 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2018 | 738 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2014 | 255 | 0.030 |
Why?
|
| Proteinuria | 1 | 2013 | 91 | 0.030 |
Why?
|
| Systole | 1 | 2013 | 191 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 531 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2012 | 101 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 516 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 123 | 0.020 |
Why?
|
| Global Health | 1 | 2014 | 329 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 853 | 0.020 |
Why?
|
| Forecasting | 1 | 2013 | 359 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2012 | 183 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 381 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 212 | 0.020 |
Why?
|
| Medical Audit | 1 | 2011 | 77 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2012 | 291 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 1220 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 2011 | 133 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2011 | 360 | 0.020 |
Why?
|
| Social Class | 1 | 2011 | 257 | 0.020 |
Why?
|
| Health Care Rationing | 1 | 2008 | 57 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 1894 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 59 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2535 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 2282 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1565 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 3717 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 20393 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 35361 | 0.010 |
Why?
|